Breast Cancer Research and Treatment

, Volume 99, Issue 3, pp 313–321 | Cite as

Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women

  • Dawn L. Hershman
  • Xiaoyan Wang
  • Russell McBride
  • Judith S. Jacobson
  • Victor R. Grann
  • Alfred I. Neugut
Epidemiology

Summary

Background

Delay in the diagnosis of breast cancer is associated with worse stage distribution at diagnosis and decreased survival. However, the occurrence of delay in the delivery of adjuvant therapy and its impact on prognosis is not well understood.

Methods

To investigate the timeliness of initiation of adjuvant chemotherapy following surgery for breast cancer, we used data from the Surveillance, Epidemiology, and End-Results (SEER)–Medicare database. Among women ≥ 65 years diagnosed between 1992 and 1999 with stages I–II breast cancer, we used linear regression and Cox proportional hazards models to investigate the time intervals between surgery and initiation of adjuvant chemotherapy, factors associated with delay, and the effect of delay on survival.

Results

Our sample consisted of 5003 women who received adjuvant chemotherapy. Of these, 47% initiated chemotherapy within 1 month, 37% between 1 and 2 months, 6% between 2 and 3 months and 10% >3 months (delay) following surgery. Delay was associated with increasing age, residing in a rural location, being unmarried, earlier tumor stage, hormone receptor positivity, mastectomy, and non-receipt of radiation therapy. Survival did not differ among patients who initiated chemotherapy within 1, 2, or 3 months after surgery. Delay beyond 3 months was, however, associated with increased disease-specific mortality (HR 1.69; 95% CI 1.31–2.19) and overall mortality (HR 1.46; 95% CI 1.21–1.75).

Conclusions

Among older patients, moderate delays in the receipt of adjuvant chemotherapy occur frequently, but long delays (>3 months) are uncommon. While early initiation of therapy is no benefit, significant delays are associated with increased mortality. Whether this reflects the medical impact of the delay of chemotherapy or factors associated with delay is unclear, but until this is clarified, patients should be encouraged to initiate treatment without significant delay.

Keywords

breast cancer chemotherapy delay elderly SEER–Medicare 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Coburn NG, Chung MA, Fulton J, Cady B (2004) Decreased breast cancer tumor size, stage, and mortality in Rhode Island: an example of a well-screened populationCancer Control 11: 222–230PubMedGoogle Scholar
  2. 2.
    Caplan LS, Helzlsouer KJ, Shapiro S, Freedman LS, Coates RJ, Edwards BK (1995). System delay in breast cancer in whites and blacksAm J Epidemiol 142: 804–812PubMedGoogle Scholar
  3. 3.
    Caplan LS, Wells BL, Haynes S (1992). Breast cancer screening among older racial/ethnic minorities and whites: barriers to early detectionJ Gerontol 47 (Spec No): 101–110PubMedGoogle Scholar
  4. 4.
    Bickell NA, Young GJ (2001). Coordination of care for early-stage breast cancer patientsJ Gen Intern Med 16: 737–742CrossRefPubMedGoogle Scholar
  5. 5.
    Freeman HP, Muth BJ, Kerner JF (1995). Expanding access to cancer screening and clinical follow-up among the medically underservedCancer Pract 3: 19–30PubMedGoogle Scholar
  6. 6.
    Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ (1999). Influence of delay on survival in patients with breast cancer: a systematic reviewLancet 353: 1119–1126CrossRefPubMedGoogle Scholar
  7. 7.
    Gwyn K, Bondy ML, Cohen DS, Lund MJ, Liff JM, Flagg EW, Brinton LA, Eley JW, Coates RJ (2004). Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinomaCancer 100: 1595–1604CrossRefPubMedGoogle Scholar
  8. 8.
    Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thurlimann B, Holmberg S, Veronesi A, Marini G, Goldhirsch A (2000). Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study GroupJ Clin Oncol 18: 584–590PubMedGoogle Scholar
  9. 9.
    Shannon C, Ashley S, Smith IE (2003). Does timing of adjuvant chemotherapy for early breast cancer influence survival?J Clin Oncol 21: 3792–3797CrossRefPubMedGoogle Scholar
  10. 10.
    Cold S, During M, Ewertz M, Knoop A, Moller S (2005). Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG)Br J Cancer 93: 627–632CrossRefPubMedGoogle Scholar
  11. 11.
    Pronzato P, Campora E, Amoroso D, Bertelli G, Botto F, Conte PF, Sertoli MR, Rosso R (1989). Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancerAm J Clin Oncol 12: 481–485PubMedCrossRefGoogle Scholar
  12. 12.
    Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA (1982). Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancerBreast Cancer Res Treat 2: 163–169CrossRefPubMedGoogle Scholar
  13. 13.
    Klabunde CN, Warren JL, Legler JM (2002). Assessing comorbidity using claims data: an overviewMed Care 40: IV-26–IV-35CrossRefGoogle Scholar
  14. 14.
    Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB (2002). Utility of the SEER–Medicare data to identify chemotherapy useMed Care 40: IV-55–IV-61Google Scholar
  15. 15.
    Bach PB, Cramer LD, Warren JL, Begg CB (1999). Racial differences in the treatment of early-stage lung cancerN Engl J Med 341: 1198–1205CrossRefPubMedGoogle Scholar
  16. 16.
    Charlson ME, Sax FL, MacKenzie CR, Fields SD, Braham RL, Douglas RG Jr. (1986). Assessing illness severity: does clinical judgment work?J Chronic Dis 39: 439–452CrossRefPubMedGoogle Scholar
  17. 17.
    Deyo RA, Cherkin DC, Ciol MA (1992). Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJ Clin Epidemiol 45: 613–619CrossRefPubMedGoogle Scholar
  18. 18.
    Klabunde CN, Potosky AL, Legler JM, Warren JL (2000). Development of a comorbidity index using physician claims dataJ Clin Epidemiol 53: 1258–1267CrossRefPubMedGoogle Scholar
  19. 19.
    Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ (2003). Does delay in starting treatment affect the outcomes of radiotherapy? A systematic reviewJ Clin Oncol 21: 555–563CrossRefPubMedGoogle Scholar
  20. 20.
    Caplan LS, Helzlsouer KJ, Shapiro S, Wesley MN, Edwards BK (1996). Reasons for delay in breast cancer diagnosisPrev Med 25: 218–224CrossRefPubMedGoogle Scholar
  21. 21.
    Shavers VL, Harlan LC, Stevens JL (2003) Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35Cancer 97: 134–147CrossRefPubMedGoogle Scholar
  22. 22.
    Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M (2003). Trends in breast cancer by race and ethnicityCA Cancer J Clin 53: 342–355PubMedCrossRefGoogle Scholar
  23. 23.
    Vercelli M, Lillini R, Capocaccia R, Micheli A, Coebergh JW, Quinn M, Martinez-Garcia C, Quaglia A (2006) Cancer survival in the elderly: effects of socio-economic factors and health care system features (ELDCARE project)Eur J Cancer 42: 234–242CrossRefPubMedGoogle Scholar
  24. 24.
    Neal RD, Allgar VL (2005). Sociodemographic factors and delays in the diagnosis of six cancers: analysis of data from the “National Survey of NHS Patients: Cancer”Br J Cancer 92: 1971–1975CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Dawn L. Hershman
    • 1
    • 2
    • 3
  • Xiaoyan Wang
    • 2
  • Russell McBride
    • 2
  • Judith S. Jacobson
    • 2
  • Victor R. Grann
    • 1
    • 2
    • 3
  • Alfred I. Neugut
    • 1
    • 2
    • 3
  1. 1.Department of Medicine and the Herbert Irving Comprehensive Cancer CenterCollege of Physicians and Surgeons Columbia UniversityNew YorkUSA
  2. 2.Department of EpidemiologyMailman School of Public Health, Columbia UniversityNew YorkUSA
  3. 3.New York Presbyterian HospitalNew YorkUSA

Personalised recommendations